Literature DB >> 20688049

Comparison of the pharmacological properties of human and rat histamine H(3)-receptors.

David Schnell1, Andrea Strasser, Roland Seifert.   

Abstract

Ligand pharmacology of histamine H(3)-receptors is species-dependent. In previous studies, two amino acids in transmembrane domain 3 (TM III) were shown to play a significant role. In this study, we characterized human and rat histamine H(3)-receptors (hH(3)R and rH(3)R, respectively), co-expressed with mammalian G proteins in Sf9 insect cell membranes. We compared a series of imidazole-containing H(3)R ligands in radioligand binding and steady-state GTPase assays. H(3)Rs similarly coupled to Gα(i/o)-proteins. Affinities and potencies of the agonists histamine, N(α)-methylhistamine and R-(α)-methylhistamine were in the same range. Imetit was only a partial agonist. The pharmacology of imetit and proxifan was similar at both species. However, impentamine was more potent and efficacious at rH(3)R. The inverse agonists ciproxifan and thioperamide showed higher potency but lower efficacy at rH(3)R. Clobenpropit was not species-selective. Strikingly, imoproxifan was almost full agonist at hH(3)R, but an inverse agonist at rH(3)R. Imoproxifan was docked into the binding pocket of inactive and active hH(3)R- and rH(3)R-models and molecular dynamic simulations were performed. Imoproxifan bound to hH(3)R and rH(3)R in E-configuration, which represents the trans-isomer of the oxime-moiety as determined in crystallization studies, and stabilized active hH(3)R-, but inactive rH(3)R-conformations. Large differences in electrostatic surfaces between TM III and TM V cause differential orientation of the oxime-moiety of imoproxifan, which then differently interacts with the rotamer toggle switch Trp(6.48) in TM VI. Collectively, the substantial species differences at H(3)Rs are explained at a molecular level by the use of novel H(3)R active-state models.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688049     DOI: 10.1016/j.bcp.2010.07.027

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Commercially available antibodies against human and murine histamine H₄-receptor lack specificity.

Authors:  Silke Beermann; Roland Seifert; Detlef Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-10       Impact factor: 3.000

2.  Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics.

Authors:  Heidrun Appl; Tobias Holzammer; Stefan Dove; Ekkehard Haen; Andrea Strasser; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-10-28       Impact factor: 3.000

3.  Expression and functional properties of canine, rat, and murine histamine H₄ receptors in Sf9 insect cells.

Authors:  David Schnell; Irena Brunskole; Katerina Ladova; Erich H Schneider; Patrick Igel; Stefan Dove; Armin Buschauer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-27       Impact factor: 3.000

Review 4.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 5.  Pharmacological Characterization of Human Histamine Receptors and Histamine Receptor Mutants in the Sf9 Cell Expression System.

Authors:  Erich H Schneider; Roland Seifert
Journal:  Handb Exp Pharmacol       Date:  2017

Review 6.  Molecular and cellular analysis of human histamine receptor subtypes.

Authors:  Roland Seifert; Andrea Strasser; Erich H Schneider; Detlef Neumann; Stefan Dove; Armin Buschauer
Journal:  Trends Pharmacol Sci       Date:  2012-12-17       Impact factor: 14.819

7.  Synthesis, biological evaluation, and computational studies of Tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and hH3 receptor antagonists.

Authors:  Fouad H Darras; Steffen Pockes; Guozheng Huang; Sarah Wehle; Andrea Strasser; Hans-Joachim Wittmann; Martin Nimczick; Christoph A Sotriffer; Michael Decker
Journal:  ACS Chem Neurosci       Date:  2014-01-14       Impact factor: 4.418

8.  Pharmacological profile of astemizole-derived compounds at the histamine H1 and H4 receptor--H1/H4 receptor selectivity.

Authors:  Eva Wagner; Hans-Joachim Wittmann; Sigurd Elz; Andrea Strasser
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-17       Impact factor: 3.000

9.  Histamine h3 receptor: a novel therapeutic target in alcohol dependence?

Authors:  Saara Nuutinen; Jenni Vanhanen; Tiia Mäki; Pertti Panula
Journal:  Front Syst Neurosci       Date:  2012-05-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.